Melanoma
Melanoma is a type of cancer that begins in melanocytes, the cells that make pigment in the skin. It can also arise in other pigmented tissues, but it is most often discussed as a skin cancer.
Melanoma is a condition in oncology. This page gives a simple overview to help you understand the topic and what it refers to.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
May not suit people with this condition
Supplements and practices linked to problems for people with this condition.
Black SalvepracticeLikely
Case reports describe melanoma progression after application, as well as tissue necrosis and cellulitis after self-treatment; they provide no evidence of efficacy. Earlier reports also describe incomplete eradication and progression.
Open the Black Salve page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this conditionNothing in this library is currently recorded as helping with Melanoma. That means nothing is on file — not that nothing exists. Only 107 of 338 catalogued supplements have a written-up profile so far.
What to avoid
Interventions recorded as making it worse1 listedHighest probability
- →PracticesBlack SalveCertaintyHighSourceClinical
Case reports describe melanoma progression after application, as well as tissue necrosis and cellulitis after self-treatment; they provide no evidence of efficacy. Earlier reports also describe incomplete eradication and progression.
Who was studied
- People with a condition
- Melanoma
Study result
Case report showing progression of melanoma after black salve application; no evidence of efficacy.
Open Black SalveRationale
Case report showing progression of melanoma after black salve application; no evidence of efficacy.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Melanoma is a type of cancer that begins in melanocytes, the cells that make pigment in the skin. It can also arise in other pigmented tissues, but it is most often discussed as a skin cancer.
In this library, melanoma is listed as a condition that may be associated with certain supplements or compounds, with some marked as potentially helpful and others as ones to avoid. Because the available data here is limited, it is best understood as a condition requiring careful clinical evaluation and individualized guidance.
Evidence-backed options
A few options have been studied for melanoma, but the evidence is limited and the likelihood of benefit is low. Dihydromyricetin (DHM) is supported by a review, Fisetin by animal research, and Metformin by an RCT. That means these findings are preliminary and do not establish a clear, reliable effect.
Because the evidence base is narrow, these options are best understood as research signals rather than established treatments. The different evidence types also matter: animal research is an early step, reviews can summarize existing findings but depend on the underlying studies, and an RCT is more direct but still does not by itself prove broad effectiveness. A clinician can help interpret whether any of these findings are relevant in the context of an individual diagnosis and overall care plan.
What to avoid
For melanoma, the main items to avoid are substances that may be relevant to melanocyte-related pathways or are flagged in pharmacology references as not appropriate for this condition. The strongest avoid signals in the provided data are for L-DOPA (Levodopa), Melanotan II, and Mucuna Pruriens.
The data also flags DL-Phenylalanine (DLPA) and Tyrosine with a medium avoid probability, while N-Acetyl-L-Tyrosine (NALT) and Phenylalanine are listed with very low avoid probability. Because these labels reflect different levels of evidence and certainty, they should be read as a cautionary reference rather than a diagnosis-specific treatment rule.
If someone has melanoma, it is reasonable to review any supplement or medication that overlaps with these names with a clinician, especially before using products marketed for tanning, pigmentation, energy, or amino acid support. The provided data does not include details on dosing, timing, or specific scenarios, so those factors should be assessed individually in clinical context.